# Availability

## Current Capacity
- **Percent available:** 40%
- **Primary commitment:** ADRIATIC trial follow-up assays (Q2 deadline), durvalumab reproducibility analysis
- **Preferred project size:** Small advisory roles (2-4 hours/week) or focused validation sprints
- **Timezone:** US Pacific (PT)

## Schedule Constraints
- Q2 2026: ADRIATIC assays are non-negotiable — 60% of time committed
- Lab time cannot be interrupted for meetings — block 8am-12pm daily
- Assay turnaround: 3 weeks per run — "quick validation" requests are 3 weeks minimum

## Project Bandwidth

| Slot | Status | Project | Notes |
|------|--------|---------|-------|
| 1 | Active | ADRIATIC Trial Assays | Q2 deadline, non-negotiable |
| 2 | Active | Durvalumab Reproducibility | Publication target |
| 3 | Advisory | Clinical Trial Predictor | Constraint input only — not building models |

**Last updated:** 2026-02-07
